Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis
© 2024 AbbVie Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics..
Upadacitinib is an orally administered, selective, Janus kinase inhibitor that is approved for several auto-immune conditions, such as axial spondyloarthritis, an inflammatory rheumatic disease that includes ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). The approvals of upadacitinib for the treatment of AS and nr-axSpA were based on the safety and efficacy data for upadacitinib 15 mg once-daily compared to placebo from the SELECT-AXIS 1 and SELECT-AXIS 2 studies. Population pharmacokinetic analyses based on data from 244 patients with axSpA showed that the pharmacokinetics of upadacitinib were comparable in subjects with AS and nr-axSpA. Exposure-response relationships were characterized for key efficacy and safety end points using data from 482 patients with axSpA. The exposure-response analyses for efficacy based on Assessment of SpondyloArthritis International Society (ASAS)20 and ASAS40 responses at week 14, showed a clear differentiation from placebo with no evidence of increased responses with increasing upadacitinib plasma exposures. There were no clear exposure-response trends observed for safety end points that included serious infections, herpes zoster, pneumonia, lymphopenia (grade ≥3), neutropenia (grade ≥3), or a greater than 2 g/dL decrease in hemoglobin from baseline through week 14. The exposure-response analyses for efficacy and safety presented here supported the favorable benefit-risk profile with the use of upadacitinib 15 mg once-daily for the treatment of axSpA.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
---|---|
Enthalten in: |
Clinical and translational science - 17(2024), 2 vom: 04. Feb., Seite e13733 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Bhatnagar, Sumit [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antirheumatic Agents |
---|
Anmerkungen: |
Date Completed 14.02.2024 Date Revised 17.04.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.1111/cts.13733 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368350207 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368350207 | ||
003 | DE-627 | ||
005 | 20240418232552.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240213s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/cts.13733 |2 doi | |
028 | 5 | 2 | |a pubmed24n1379.xml |
035 | |a (DE-627)NLM368350207 | ||
035 | |a (NLM)38344875 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Bhatnagar, Sumit |e verfasserin |4 aut | |
245 | 1 | 0 | |a Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.02.2024 | ||
500 | |a Date Revised 17.04.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024 AbbVie Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. | ||
520 | |a Upadacitinib is an orally administered, selective, Janus kinase inhibitor that is approved for several auto-immune conditions, such as axial spondyloarthritis, an inflammatory rheumatic disease that includes ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). The approvals of upadacitinib for the treatment of AS and nr-axSpA were based on the safety and efficacy data for upadacitinib 15 mg once-daily compared to placebo from the SELECT-AXIS 1 and SELECT-AXIS 2 studies. Population pharmacokinetic analyses based on data from 244 patients with axSpA showed that the pharmacokinetics of upadacitinib were comparable in subjects with AS and nr-axSpA. Exposure-response relationships were characterized for key efficacy and safety end points using data from 482 patients with axSpA. The exposure-response analyses for efficacy based on Assessment of SpondyloArthritis International Society (ASAS)20 and ASAS40 responses at week 14, showed a clear differentiation from placebo with no evidence of increased responses with increasing upadacitinib plasma exposures. There were no clear exposure-response trends observed for safety end points that included serious infections, herpes zoster, pneumonia, lymphopenia (grade ≥3), neutropenia (grade ≥3), or a greater than 2 g/dL decrease in hemoglobin from baseline through week 14. The exposure-response analyses for efficacy and safety presented here supported the favorable benefit-risk profile with the use of upadacitinib 15 mg once-daily for the treatment of axSpA | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Antirheumatic Agents |2 NLM | |
700 | 1 | |a Eckert, Doerthe |e verfasserin |4 aut | |
700 | 1 | |a Stodtmann, Sven |e verfasserin |4 aut | |
700 | 1 | |a Song, In-Ho |e verfasserin |4 aut | |
700 | 1 | |a Wung, Peter |e verfasserin |4 aut | |
700 | 1 | |a Liu, Wei |e verfasserin |4 aut | |
700 | 1 | |a Mohamed, Mohamed-Eslam F |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical and translational science |d 2008 |g 17(2024), 2 vom: 04. Feb., Seite e13733 |w (DE-627)NLM186388268 |x 1752-8062 |7 nnns |
773 | 1 | 8 | |g volume:17 |g year:2024 |g number:2 |g day:04 |g month:02 |g pages:e13733 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/cts.13733 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 17 |j 2024 |e 2 |b 04 |c 02 |h e13733 |